Medically reviewed by Kashif J. Piracha, MD Key Takeaways Hypovolemia is a severe loss of body fluids and can lead to organ ...

In one of the largest studies of early cardiogenic shock (CS) patients, where blood flow is still functioning to vital organs, researchers demonstrated that 26% experienced worse outcomes, including ...

Elevating patients with cardiogenic shock (CS) to mechanical circulatory support (MCS) early on could yield greater reductions in mortality due to CS, as opposed to the strategy of managing patients ...

WASHINGTON, DC—Early-stage cardiogenic shock leads to poor outcomes but is underrecognized, with only one in four affected patients having any indication in their electronic medical record (EMR) that ...

Baylor Scott & White The Heart Hospital-Plano in Texas cut times of cardiogenic shock diagnosis in half after implementing a quality improvement project that included nurse education and an electronic ...

The American College of Cardiology (ACC) has issued its first Concise Clinical Guidance (CCG) to create more streamlined and efficient processes to implement best practices in patient care. This CCG ...

Patients with heart failure and adrenal insufficiency, compared with heart failure alone, have worse outcomes and a higher health care burden.

Compared with crushed ticagrelor, intravenous cangrelor provided immediate, effective platelet inhibition, with no increase in major bleeding and lower mortality rates in patients with acute ...

Lactate clearance can be used to predict survival in patients with cardiogenic shock and aid in management decisions, and experts are calling for establishing lactate clearance as a standardized, ...

WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has unveiled new data on istaroxime, a treatment candidate for cardiogenic shock, at the European Society of Cardiology Heart Failure 2025 ...

Nursing staff interventions regarding shock team activation significantly improved the time of diagnosis and acceptance of patients with cardiogenic shock. A cardiovascular specialty hospital in north ...

Windtree Therapeutics, Inc. announced that it is preparing for an interim analysis of its SEISMiC C Phase 2 study of istaroxime, targeting results for July 2025. This global, placebo-controlled, ...